Meduslabs — Evidence-based health research
Home›Cancer›Leukaemia: Symptoms, Types, Treatment, and Immune Support
Key Takeaways

Leukaemia is one of the most serious blood diseases, caused by abnormal formation and growth of blood cells. It can affect people of any age, but it most often appears in older people.

Leukaemia symptoms

Symptoms can differ depending on the type of leukaemia. The general symptoms are persistent weakness and fatigue, fever, weight loss, and an increased risk of infection.

Types of leukaemia

Leukaemia is divided into two main categories: acute and chronic. Each type has different symptoms and requires different treatment. Leukaemia is also classified by the type of affected cell — lymphocytic and myeloid.

Leukaemia treatment

Several treatment methods may be used, including chemotherapy, radiotherapy, and stem-cell (bone-marrow) transplantation. The choice depends on the disease type, severity, and the patient's condition.

Chemotherapy is one of the most effective treatments for leukaemia. It uses drugs that destroy rapidly dividing cells. It can cause side effects but is widely used, because the benefit of chemotherapy usually outweighs the harm. Radiotherapy uses radiation to destroy leukaemia cells and is often used as an additional method alongside chemotherapy to increase treatment effectiveness. Stem-cell transplantation may be used in some cases to replace damaged bone marrow with healthy blood-forming cells.

Can I help myself further?

You can control the factors that depend on you. Getting your diet in order is essential — it helps the immune system work more effectively, and makes cancer treatment (such as chemotherapy) even more effective. With natural supplements extracted from medicinal mushrooms (such as Lentinan), you can help the immune system fight. Effectiveness depends on the dose and the length of use. Physical activity and breathing exercises (for example the Wim Hof method) are also advisable. Cancer knows how to send cloaking signals, so the immune system finds it hard to detect — concentrated mushroom-polysaccharide formulas are studied for their role in strengthening the immune response during oncological disease.

Related supplement

Leukaemia and chemotherapy both suppress the immune system. Concentrated mushroom polysaccharides are studied for their role in supporting NK-cell and macrophage activity.

Lentinan AXT by Zenius Labs™ →
What is leukaemia?

Leukaemia is a cancer of the blood and bone marrow in which the body produces too many immature white blood cells. These altered cells cannot fight infection properly and interfere with the production of normal blood cells.

Do you need to support the immune system with leukaemia?

Yes. Leukaemia directly damages the immune system, and chemotherapy suppresses it further. Concentrated mushroom-polysaccharide extracts are studied for their role in activating NK cells and macrophages. It is important to choose a concentrated multi-extract formula such as Lentinan AXT by Zenius Labs™.

What are the main types of leukaemia?

Leukaemia is divided into acute (fast-progressing) and chronic (slow-developing), and also by the type of affected cell — lymphocytic and myeloid. Each type is treated differently, so an accurate diagnosis is very important.

What are the symptoms of leukaemia?

Common symptoms include persistent fatigue, frequent infections, unexplained fever, night sweats, easy bleeding or bruising, bone and joint pain, and weight loss.

How is leukaemia treated?

The main treatment is chemotherapy, which may be combined with radiotherapy, targeted therapy, or stem-cell transplantation. Immune support during and after treatment is very important for recovery.

References
  1. Acute myeloid leukaemia. PubMed
  2. Recent advances in targeted therapies in acute myeloid leukemia. PubMed
  3. Targeted Therapy in Chronic Lymphocytic Leukemia. PubMed
  4. Tani M et al. In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan. European journal of clinical pharmacology. 1992. PubMed
  5. Hamano K et al. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. International journal of immunopharmacology. 1999. PubMed
  1. Mattiola I et al. The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. Nature immunology. 2019. PubMed
  2. Zhou X et al. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. The oncologist. 2008. PubMed
  3. Li B et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. Journal of immunology (Baltimore, Md. : 1950). 2006. PubMed
  4. Xia Y et al. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. Journal of immunology (Baltimore, Md. : 1950). 1999. PubMed
  5. Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
  6. Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
  7. Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
  8. Adachi Y et al. Potentiation of Antitumor Activity by Antibody Drugs and Mushroom-Derived β-Glucans in Natural Killer Cell-Mediated Tumoricidal Activities against Non-Hodgkin’s B-Cell Lymphoma. International journal of medicinal mushrooms. 2023. PubMed
  9. Sam J et al. Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma. Blood. 2025. PubMed
  10. Ansell SM et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. The New England journal of medicine. 2015. PubMed
  11. Azoulay T et al. Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression. Cancer immunology, immunotherapy : CII. 2023. PubMed
  12. Sato A et al. [Pathogenesis and novel therapy for EBV-related B-cell lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2016. PubMed
  13. Chen J et al. Epstein-Barr virus: biology, pathogenesis and therapy of lymphomas. Discover oncology. 2025. PubMed
  14. Liquidano-Perez E et al. Case Report: Hydroa vacciniforme-like lymphoproliferative disorder, an EBV-associated disease, successfully treated with hematopoietic stem cell transplantation. Frontiers in immunology. 2025. PubMed
  15. Song JY et al. Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma. Haematologica. 2023. PubMed
  16. Greenbaum AM et al. Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8(+) T-cells despite immune checkpoint signaling. Blood research. 2022. PubMed
  17. Liu WR et al. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood. 2017. PubMed
  18. Wang D et al. Dectin-1 stimulates IL-33 expression in dendritic cells via upregulation of IRF4. Laboratory investigation; a journal of technical methods and pathology. 2018. PubMed
  19. Engel AL et al. Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. Immunobiology. 2013. PubMed
  20. Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
  21. Oba K et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer research. 2009. PubMed
  22. Wang Y et al. Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis. Medicine. 2024. PubMed
  23. Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
  24. Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
  25. Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
  26. Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
  27. van der Meer JW et al. Trained immunity: A smart way to enhance innate immune defence. Molecular immunology. 2015. PubMed
  28. Vuscan P et al. Potent induction of trained immunity by Saccharomyces cerevisiae β-glucans. Frontiers in immunology. 2024. PubMed
  29. Zou X et al. Radioprotective effect of edible and medicinal mushrooms against ionizing radiation: Components, potential mechanisms, and applications. Food research international (Ottawa, Ont.). 2025. PubMed
  30. Liu F et al. The mechanisms for the radioprotective effect of beta-d-glucan on high linear-energy-transfer carbon ion irradiated mice. International journal of biological macromolecules. 2019. PubMed
  31. Christophersen OA Radiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposure. Microbial ecology in health and disease. 2012. PubMed
  32. Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
  33. Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
  34. Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
Zenius Labs™

Lentinan AXT — concentrated immune-support formula

Lentinan AXT by Zenius Labs™ combines Lentinus edodes and Coriolus versicolor polysaccharides with astaxanthin in a concentrated, precision formula — designed to strengthen the immune response during oncological disease.

Get Lentinan AXT